On Feb. 2, 2022, a new analysis of the first two patients treated in a clinical trial with…
On Feb. 2, 2022, President Biden announced a reignition of the Cancer Moonshot, that highlighted new goals: to…
On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…
On Jan. 27, 2022, Cocrystal Pharma announced that it had selected two investigational novel antiviral drug candidates for…
On Jan. 26, 2022, a former University of British Columbia post-doctoral research fellow led an international research team…
The Evolution of CRISPR illustrates its climb out of the primordial ocean on the backs of eukaryotic cells…
On Jan. 24, 2022, Atara Biotherapeutics, a leader in T-cell immunotherapy, announced that it had leveraged its novel…
On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they…
On Jan. 20, 2022, a clinical trial funded by the National Institutes of Health found that giving peanut…
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
On Jan. 12, 2022, Pfizer announced positive top-line results from a Phase 3 study describing the safety and…
On Jan. 4, 2022, Pfizer announced that the U.S. government had committed to purchasing an additional 10 million…
Our Heroes and Remembrance illustration has Maurice Ralph Hilleman and John Enders, pioneering developers of common vaccines, and…
On Dec. 24, 2021, Merck and Ridgeback Biotherapeutics announced that Japanï¾’s Ministry of Health, Labor and Welfare had…
On Dec. 23, 2021, Merck and Ridgeback Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) had…
On Dec. 23, 2021, Pfizer and BioNTech announced that they had submitted longer-term follow-up data from the companiesï¾’…
On Dec. 22, 2021, Gilead Sciences announced full results from a Phase 3 investigational study evaluating the efficacy…
On Dec. 22, 2021, Cocrystal Pharma announced that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main…
On Dec. 22, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…
On Dec. 21, 2021, the University of Oxford’s vaccine manufacturing research team published a pre-print paper demonstrating the…
On Dec. 20, 2021, Pfizer and BioNTech announced an agreement had been reached with the European Commission (EC)…
On Dec. 14, 2021, Pfizer announced final results from an analysis of all 2,246 adults enrolled in its…
On Dec. 9, 2021, CytoDyn announced that it had submitted a Phase 3, randomized, double blind, placebo controlled…
On Dec. 8, 2021, Pfizer and BioNTech announced results from an initial laboratory study demonstrating that serum antibodies…
On Dec. 8, 2021, in a large-scale study of people from diverse ancestries, researchers narrowed down the number…
On Dec. 7, 2021, Rockefeller University scientists announced a study had demonstrated the therapeutic potential of an unusual…
On Dec. 5, 2021, Sorrento Therapeutics announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors…
On Dec. 1, 2021, SIGA Technologies announced that Health Canada had approved oral TPOXX (tecovirimat) as an extraordinary…
The COVID-19 Roller Coaster is a wild ride, strap yourself in and hold on… Cast of Characters: Senator…
On Nov. 26, 2021, Merck provided an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral…